TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05810467

Intervention type: OTHER
Intervention: Active Surveillance
Description: Active surveillance (AS) is an accepted management strategy for men diagnosed with low risk PrCa, generally defined as PSA \<10ng/ml and Gleason score of ≤6 and clinical stage T1 to T2a. Occasionally, a minority of men with Gleason 3+4 disease are included, though majority of those included in AS studies have Gleason 3+3 disease or less.~Men in AS studies have repeated biopsies based on various criteria including PSA velocity, repeat biopsy at set time points and change noted on digital rectal examination (DRE), biopsy or MRI imaging. Progression of disease has been defined in various ways in different studies, generally, using criteria of Gleason upgrade to greater than Gleason 3+3, evidence of Gleason 4 or Gleason 5 disease, \>50% involvement of any one biopsy core, and greater than 2 cores positive on repeat biopsy. Percentages of men on AS who have upgrade on repeat biopsy have been found to be 19-34%; this may differ in our cohort of men with increased genetic risk for PrCa.

Intervention type: OTHER
Intervention: Active Surveillance
Description: Active surveillance (AS) is an accepted management strategy for men diagnosed with low risk PrCa, generally defined as PSA \<10ng/ml and Gleason score of ≤6 and clinical stage T1 to T2a. Occasionally, a minority of men with Gleason 3+4 disease are included, though majority of those included in AS studies have Gleason 3+3 disease or less.~Men in AS studies have repeated biopsies based on various criteria including PSA velocity, repeat biopsy at set time points and change noted on digital rectal examination (DRE), biopsy or MRI imaging. Progression of disease has been defined in various ways in different studies, generally, using criteria of Gleason upgrade to greater than Gleason 3+3, evidence of Gleason 4 or Gleason 5 disease, \>50% involvement of any one biopsy core, and greater than 2 cores positive on repeat biopsy. Percentages of men on AS who have upgrade on repeat biopsy have been found to be 19-34%; this may differ in our cohort of men with increased genetic risk for PrCa.
Study: NCT05553236

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Targeted next-generation sequencing
Description: During intervention periods, an additional patient sample derived from routinely collected specimens will be processed by a local technician. Extracted DNA extracted from these samples will be batched on a regular basis for targeted deep sequencing. Sequencing results will be regularly transmitted to a clinical advisory committee.
Study: NCT05110261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirsevimab
Description: Drug: injection, 100 mg/mL, a single fixed IM dose of 50 mg (if weight \< 5 kg) or 100 mg (if weight ≥ 5 kg)on day 1 only.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Commercially available 0.9% (w/v) saline (sterile for human use) fixed IM dose of 0.5 mL (if weight \<5 kg) or 1.0 mL (if weight \>=5 kg)
Study: NCT06120842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost Implant System (High Dose)
Description: Bimatoprost Implant System (High Dose) used in combination with the SpyGlass IOL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost Implant System (Low Dose)
Description: Bimatoprost Implant System (Low Dose) used in combination with the SpyGlass IOL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol Maleate Ophthalmic Solution, 0.5%
Description: Timolol Maleate Ophthalmic Solution 0.5% BID

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Commercially Available Aspheric Monofocal Non-Yellow Chromophore IOL
Description: Commercially Available Aspheric Monofocal Non-Yellow Chromophore Intraocular Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpyGlass IOL
Description: SpyGlass Intraocular Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpyGlass IOL
Description: SpyGlass Intraocular Lens
Study: NCT06317909

Intervention type: OTHER
Group type: OTHER
Intervention: allergen challenge
Description: Patients will undergo inhaled allergen challenge followed by different measures like MRI and induced sputum. At least 4 weeks later patients will undergo segmental allergen challenge followed by different measures like bronchoalveolar lavage.
Study: NCT06396325

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tales from the Magic Keep™
Description: Exergame targeting upper limb and trunk movement designed for use on the Microsoft Azure Kinect Dose: At least 3 times a week for 20 minutes over 8 weeks (8 hours total) Continue with regularly accessed physical activities and rehabilitation services

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: •Continue with regularly accessed physical activities and rehabilitation services
Study: NCT05229705

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: Participants in this exercise group will receive progressive resistance training.
Study: NCT06463730

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Serious games
Description: Custom games played using the Equio system, non-custom Wii Fit games played using the Nintendo Wii Balance Board

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Serious games
Description: Custom games played using the Equio system, non-custom Wii Fit games played using the Nintendo Wii Balance Board

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Serious games
Description: Custom games played using the Equio system, non-custom Wii Fit games played using the Nintendo Wii Balance Board
Study: NCT05877768

Intervention type: DIAGNOSTIC_TEST
Intervention: Photon Counting Detector Coronary Computed Tomography Angiography
Description: Clinically indicated Photon Counting Detector Coronary Computed Tomography Angiography for the suspicion of coronary artery disease or the progression thereof.
Study: NCT05920278

Intervention type: DEVICE
Intervention: Pulse oximeter
Description: Devices (2) were placed on the finger and the fingertip. Blood samples were taken at each stable level of oxygenation.
Study: NCT06098651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCR-STAT3
Description: DCR-STAT3 is a sterile, preservative-free solution in WFI that will be diluted in a suitable admixture diluent (0.9% normal saline) prior to IV infusion.
Study: NCT05404451

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Mulligan Mobilization
Description: Using the Technique of Mulligan Mobilization

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Mckenzie Exercises
Description: Using Mckenzie Exercises
Study: NCT05555927

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS)
Description: Transcranial direct current stimulation is an non-invasive brain stimulation that is proposed as a possible interventional tool for major depressive disorder. tDCS device that this study used is from Neuroelectrics, Starstim 8, USA.
Study: NCT06463730

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Serious games
Description: Custom games played using the Equio system, non-custom Wii Fit games played using the Nintendo Wii Balance Board
Study: NCT04281940

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter implantation of chordal repair system
Description: Implantation of anchor via transcatheter delivery system to delivery chordal repair system tethering the mitral leaflets to the ventricle
Study: NCT05555927

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS)
Description: Transcranial direct current stimulation is an non-invasive brain stimulation that is proposed as a possible interventional tool for major depressive disorder. tDCS device that this study used is from Neuroelectrics, Starstim 8, USA.
Study: NCT06013111

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous infusion anti-CEA-CAR-T cell
Description: Anti-CEA-CAR-T cell is administered as a single intravenous infusion. Follow-up infusions are based on the investigator's decision.The dose group to be infusion was 0.3×10\^7 CAR-T cells/kg, 1×10\^7 CAR-T cells/kg, and 3×10\^7 CAR-T cells/kg based on the 3+3 dose escalation principle. The infusion dose refers to the number of CAR-positive cells.
Study: NCT06636942

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression
Description: Following a soccer match, athletes will be enrolled in a recovery treatment: placebo intervention or intermittent pneumatic compression. Participants will be randomly assigned to each group. Neuromuscular tests (cmj) and perceptual questionnaires (hooper index) will be conducted.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Intermittent pneumatic compression
Description: Following a soccer match, athletes will be enrolled in a recovery treatment: placebo intervention or intermittent pneumatic compression. Participants will be randomly assigned to each group. Neuromuscular tests (cmj) and perceptual questionnaires (hooper index) will be conducted.
Study: NCT06643091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Nintedanib150 mg twice a day for 6 months Or Nintedanib 100mg twice a day in case of dose adjustment Oral route (during meals)
Study: NCT06641609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose-Escalation (Phase Ia) CFT8919 capsule
Description: Phase 1a，enrolled, eligible patients receive CFT8919 150-900mg twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose-Expansion (Phase Ib) CFT8919 capsule
Description: Phase 1b，enrolled, eligible patients receive CFT8919 RP2D twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort-Expansion (Phase Ic) CFT8919 capsule
Description: Phase 1c，enrolled, eligible patients receive CFT8919 RP2D twice daily.
Study: NCT06010719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: oral azithromycin (20 mg/kg, single directly observed dose, oral suspension),

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Standard of Care. A 7-day, twice-daily course of amoxicillin will be offered as a syrup to children (80 mg/kg divided into twice-daily doses, estimated with weight-based dosing).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A 7-day, twice-daily course of placebo will be offered as a syrup to children (80 mg/kg divided into twice-daily doses, estimated with weight-based dosing).
Study: NCT06320782

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calorie restriction and balanced distribution of macronutrients
Description: Progressive reduction of 500 to 1000 calories from the usual food intake or the recommendation of 20 calories/kg of current weight/day and distribution of macronutrients: 5% of carbohydrates, 2% of proteins and 3% of fats

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calorie restriction and low-carbohydrate diet
Description: Reduction in carbohydrate consumption and an increase in fat and protein intake, with the following proportions: 45% fat, 20% protein and 35% carbohydrate

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calorie restriction and low-fat diet
Description: Restriction of fat consumption and an increase in carbohydrate consumption, with the following proportions: 20% fat, 15% protein and 65% carbohydrate

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collective nutritional guidance
Description: Recommendations of the Food Guide for the Brazilian Population: limitation of the intake of foods with high energy density from fats and simple carbohydrates; substitution of saturated fats for unsaturated fats; exclusion of trans fat from the diet; increasing fruit and vegetable consumption to a daily minimum of 400g; increased consumption of high-fibre foods and limiting the consumption of sugars and salt.
Study: NCT05826626

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MindLenses Professional
Description: MindLenses professional's device combines the prismatic adaptation (PA) procedure with the administration of serious games (SG) for cognitive training using a tablet
Study: NCT06601751

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurobic Exercise Program
Description: 6 weeks to improve cognitive function, memory and overall brain health by introducing non-routine activities that require participants to utilise their multiple senses and remember sequences and patterns. Each activity would be performed 2-3 times/ session, for recalling the observation period set at 1 minute and at the end of the 9th week, the memory retention effect will be measured.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Brain Exercise
Description: activities like calculation or memory games. These exercises will be conducted in 2 days/week for 60-minute sessions in 6 weeks. The memory retention effect will be measured at the end of the 9th week. It is intended to be the baseline for comparing the effectiveness of a neurobic exercise program.
Study: NCT06611150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: All participants enrolled in the study will be treated with nab-paclitaxel during radical radiotherapy following induction chemotherapy. The doses are increased progressively (180 mg/m², 200 mg/m², 230 mg/m², and 260 mg/m²).
Study: NCT06614907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL2108 injection
Description: 300mg/2.0mL; single dose; prefilled syringe; subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dupixent®
Description: 300mg/2.0mL; single dose; prefilled syringe; subcutaneous injection
Study: NCT06616805

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: treadmill
Description: Treadmill JAGUAR treadmill:( T900, China) motorized treadmill model (T900) motor power (6.OHP) input voltage (AC220-240 V, 50Hz) speed range (1-20KM/H), inclination range (1-15%) was used for exercise treatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: treadmill
Description: Treadmill JAGUAR treadmill:( T900, China) motorized treadmill model (T900) motor power (6.OHP) input voltage (AC220-240 V, 50Hz) speed range (1-20KM/H), inclination range (1-15%) was used for exercise treatment
Study: NCT06616389

Intervention type: DRUG
Group type: OTHER
Intervention: ODX (Osteodex)
Description: Multi-center, prospective, open-label, ascending dose study to evaluate safety and biological efficacy of up to 3 dose levels of ODX.
Study: NCT06617663

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EMDR
Description: Eye Movement Desensitization and Reprocessing (EMDR) is a therapy designed to alleviate the distress associated with traumatic memories.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMDR
Description: Eye Movement Desensitization and Reprocessing (EMDR) is a therapy designed to alleviate the distress associated with traumatic memories.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ACT
Description: Acceptance and Commitment Therapy (ACT) is an action-oriented approach to psychotherapy that stems from traditional behavior therapy and cognitive behavioral therapy. Clients learn to stop avoiding, denying, and struggling with their inner emotions and, instead, accept that these deeper feelings are appropriate responses to certain situations and should not prevent them from moving forward in their lives. The ACT Your Way method is specifically designed for young people.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT
Description: Acceptance and Commitment Therapy (ACT) is an action-oriented approach to psychotherapy that stems from traditional behavior therapy and cognitive behavioral therapy. Clients learn to stop avoiding, denying, and struggling with their inner emotions and, instead, accept that these deeper feelings are appropriate responses to certain situations and should not prevent them from moving forward in their lives. The ACT Your Way method is specifically designed for young people.
Study: NCT06675890

Intervention type: DIAGNOSTIC_TEST
Intervention: serum homocysteine
Description: serum homocysteine is associated with atherosclerosis and vascular diseases.
Study: NCT06674421

Intervention type: OTHER
Intervention: Reliability Analyses
Description: For the reliability analysis test-retest method will use. There will be a one-week break between the first test and the retest.
Study: NCT06615804

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Transcranial Magnetic Stimulation (TMS) is a non-invasive procedure that uses magnetic fields to stimulate nerve cells in the brain. It's primarily used to treat depression, especially in patients who haven't responded well to traditional treatments like medications or psychotherapy. The most common target is the dorsolateral prefrontal cortex, a region often underactive in people with depression. The magnetic pulses stimulate or inhibit brain activity in the targeted area. This is believed to help reset or correct patterns of neural activity associated with depression and other psychiatric disorders. TMS represents an alternative for those struggling with depression, offering a non-invasive approach with relatively few side effects and significant potential benefits
Study: NCT06679036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-2189
Description: HRS-2189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-2189
Description: HRS-2189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-2189
Description: HRS-2189
Study: NCT06203379

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Exercise Training
Description: Neuromuscular Exercise Training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control exercise
Description: Exercise Training
Study: NCT04863885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Description: Participants will be treated at 1 of 2 dose levels of Sacituzumab govitecan, either at 8 mg/kg, 10 mg/kg, or 6 mg/kg.
Study: NCT05826626

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MindLenses Professional
Description: MindLenses professional's device combines the prismatic adaptation (PA) procedure with the administration of serious games (SG) for cognitive training using a tablet

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: Conventional rehabilition consists in computerized exercises focused on the main cognitive domains
Study: NCT05689710

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inositol and alpha-lactalbumin
Description: The administration of an oral formulation based on inositol and alpha-lactalbumin (two sachets/day for 180 days)
Study: NCT05377879

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OPT-IVF dosage
Description: Dosage predicted for each patient by the decision support tool OPTIVF
Study: NCT04958772

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim Megalabs
Description: Filgrastim Megalabs 5 μg/Kg/day, subcutaneous single dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim Megalabs
Description: Filgrastim Megalabs 5 μg/Kg/day, subcutaneous single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Granulokine
Description: Granulokine 5 μg/Kg/day, subcutaneous single dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Granulokine
Description: Granulokine 5 μg/Kg/day, subcutaneous single dose
Study: NCT05027464

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moving to COVID-19 Vaccine Acceptance Intervention
Description: The intervention utilizes a multi-pronged approach to increase Veteran vaccine acceptance. First, the research team will train Health Behavior Coordinators (HBCs) at VAI sites. HBCs will then train PACT teams at their site and Whole Health Coaches, Peer Specialists and other VA Staff in VAI strategies to use with unvaccinated Veterans. Whole Health Coaches, Peer Specialists and other VA Staff will conduct outreach calls, using strategies, with unvaccinated Veterans.
Study: NCT05804474

Intervention type: OTHER
Intervention: Observational study
Description: Observational study

Intervention type: OTHER
Intervention: Observational study
Description: Observational study
Study: NCT04587271

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Moringa oleifera (high dose)
Description: Mothers will receive 20 grams of moringa leaf powder in porridge consumed daily for three months.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Moringa oleifera (high dose)
Description: Mothers will receive 20 grams of moringa leaf powder in porridge consumed daily for three months.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Moringa oleifera (low dose)
Description: Children will receive 5-10 grams of moringa leaf powder in porridge consumed daily for three months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mothers and children will receive porridge with placebo.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mothers and children will receive porridge with placebo.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mothers and children will receive porridge with placebo.
Study: NCT04708379

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: Nutrition and physical activity education.
Study: NCT06231732

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high-frequency transcranial alternating current stimulation
Description: The experimental group received real stimulation of high-frequency transcranial alternating current stimulation (Hi-tACS).The treatment duration is 30 days, with two sessions per day, each lasting 40 minutes.The experimental group received Hi-tACS with parameters set at 77.5Hz and 15mA

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham high-frequency transcranial alternating current stimulation
Description: The the control group received sham stimulation of high-frequency transcranial alternating current stimulation (Hi-tACS).The treatment duration is 30 days, with two sessions per day, each lasting 40 minutes.The experimental group received Hi-tACS with parameters set at 0mA
Study: NCT05246397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex administration
Description: Sugammadex will be given in 50 mg increments every five minutes for reversal of neuromuscular blockade until reaching a train-of-four ratio of 0.9
Study: NCT05203289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 695501 - higher concentration
Description: BI 695501 - higher concentration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 695501 - lower concentration
Description: BI 695501 - lower concentration
Study: NCT05677022

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted motor activity
Description: 15-month adapted motor activity program based on a postural and functional analysis